نتائج البحث

The Variation in the Traits Ameliorated by Inhibitors of JAK1/2, TGF-β, P-Selectin, and CXCR1/CXCR2 in the Gata1 low Model Suggests That Myelofibrosis Should Be Treated by These Drugs in Combination.

• Authors : Gobbo, Francesca¹ (AUTHOR) ; Martelli, Fabrizio² (AUTHOR) ; Di Virgilio, Antonio² (AUTHOR)

Subjects: *TRANSFORMING growth factors-beta; *MYELOFIBROSIS; *HEMATOPOIETIC stem cells

• Source: International Journal of Molecular Sciences. Jul2024, Vol. 25 Issue 14, p7703. 29p.

تفاصيل العنوان

Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

• Authors : Jain, T; Estrada-Merly, N; Salas, MQ

Subjects: Medicin och hälsovetenskap

• Source: Blood advances. 8(16):4281-4293

تفاصيل العنوان

Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.

• Authors : Tripodi, Joseph¹ (AUTHOR); Hoffman, Ronald² (AUTHOR); Tremblay, Douglas² (AUTHOR)

Subjects: *HETEROZYGOSITY; *COMPARATIVE genomic hybridization; *DISEASE progression

• Source: International Journal of Molecular Sciences. Apr2024, Vol. 25 Issue 7, p4061. 9p.

تفاصيل العنوان

Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis.

• Authors : Collinson RJ; School of Biomedical Sciences, The University of Western Australia, Crawley, WA, Australia.; Wilson L

Subjects: Megakaryocytes*/Megakaryocytes*/Megakaryocytes*/metabolism ; Primary Myelofibrosis*/Primary Myelofibrosis*/Primary Myelofibrosis*/genetics ; Primary Myelofibrosis*/Primary Myelofibrosis*/Primary Myelofibrosis*/pathology

• Source: Platelets [Platelets] 2024 Dec; Vol. 35 (1), pp. 2304173. Date of Electronic Publication: 2024 Feb 01.Publisher: Informa Healthcare Country of Publication: England NLM ID: 9208117 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

• Source: A Multicenter, Open-Label, Phase 1 Study of AJ1-11095 Administered as Oral Monotherapy in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera

تفاصيل العنوان

Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype.

• Authors : Beleva, Elina A.^1,2 (AUTHOR)

Subjects: *SPLANCHNIC nerves; *MYELOFIBROSIS; *THROMBOSIS

• Source: International Journal of Molecular Sciences. Nov2023, Vol. 24 Issue 21, p15717. 16p.

تفاصيل العنوان

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

• Authors : PSI CRO

• Source: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera

تفاصيل العنوان

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

• Authors : Abdulraheem Yacoub, Professor

• Source: Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM,

تفاصيل العنوان

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

• Authors : Nippon Shinyaku Co., Ltd.

• Source: A Phase 2b, Open-label, Multicenter, Randomized, Controlled, 2-Arm Study to Assess the Efficacy and Safety of Orally Administered NS-018 Versus Best Available Therapy in Subjects With Primary

تفاصيل العنوان

Extended Access of Momelotinib in Adults With Myelofibrosis

• Source: Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia

تفاصيل العنوان